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Abstract
The multi-functional adaptor protein NEDD9/HEF1/Cas-L regulates cell motility, invasion and cell cycle progression,
and plays key roles in cancer progression and metastasis. NEDD9 is localized to the centrosome and is required for
activation of Aurora A kinase in mitosis. Here we demonstrate that the HECT-WW protein Smurf2 physically associ-
ates with NEDD9 and is required for the stability of NEDD9 protein. Smurf2 depletion results in a marked decrease
in NEDD9 protein levels, by facilitating polyubiquitination and proteasomal degradation of NEDD9. Conversely,
forced overexpression of Smurf2 results in upregulation of endogenous NEDD9 protein, confirming the role for
Smurf2 in NEDD9 stability. Cells with Smurf2 depletion fail to activate Aurora A at the G2/M boundary, leading to a
marked delay in mitotic entry. These observations suggest that the stable complex of Smurf2 and NEDD9 is
required for timely entry into mitosis via Aurora A activation.
Introduction
Smurf2 (Smad ubiquitination regulatory factor 2) is a
HECT-E3 ligase that negatively regulates TGF-b signal-
ing [1]. Smurf2 targets TGF-b type I receptor, Smad1,
Smad2, Smad7, and the transcriptional repressor SnoN
for degradation by the proteasome [1-4]. In addition to
its role in TGF-b signaling, Smurf2 functions in diverse
biological pathways, including those controlling the cell
cycle and cell polarity/cytoskeletal remodeling [5-9].
Previous work from our laboratory demonstrated that
Smurf2 protein levels vary during the cell cycle, peaking
during mitosis [6]. The localization of Smurf2 also
undergoes dynamic regulation. Smurf2 is at the centro-
some from G1 through prophase, then localizes to the
spindle midzone during anaphase, and the midbody dur-
ing cytokinesis [6]. To date, the best-defined role of
Smurf2 in mitosis involves its binding to and stabiliza-
tion of Mad2, which is required for the spindle assembly
checkpoint [6].
Smurf2 contains WW domains, which mediate inter-
actions with proteins that have PPxY motifs [10], while
Mad2 does not possess any PPxY motif, suggesting
other mitosis-relevant partners might exist for Smurf2.
For further insight into the cell cycle-regulatory role of
Smurf2, we used a candidate-based approach to select
for potential Smurf2 interactors, examining those pro-
teins that both contain a PPxY-motif and exhibit a simi-
lar subcellular localization pattern. NEDD9 (neural
precursor cell expressed, developmentally down-regu-
lated 9, also called HEF1, human enhancer of filamenta-
tion 1 and Cas-L Crk-associated substrate related,
lymphocyte-type) is a scaffold protein that contains a
PPxY motif [11]. NEDD9 displays similar protein
expression and localization pattern as Smurf2, rising in
G2 and decreasing after mitosis, localizing to the centro-
some, midzone, and midbody [12]. The localization of
NEDD9 to the centrosome is required for proper mito-
tic entry [12]. The cell cycle-regulatory function of
NEDD9 is mediated, at least partly, by its role for the
activation of Aurora A kinase. Centrosomal Aurora A
activity is a critical step for mitotic entry from the G2
phase, required for the initial activation of Cyclin B-
CDK1 at the centrosome [13]. Among the elements
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recruited to the centrosome at the G2/M boundary are
the activators of Aurora A, such as Ajuba, TPX2 and
NEDD9. Thus, NEDD9 plays a significant role in trig-
gering coordinated activation of the mitotic kinase cas-
cade from Aurora A to Cyclin B-CDK1 and perhaps
other mitotic kinases required for proper progression of
mitosis [14].
To date, the upstream mechanisms that control the
level of NEDD9 protein during mitotic progression have
been poorly understood. Here we demonstrate that
Smurf2 regulates NEDD9 levels by preventing its protea-
somal degradation and this control is rate-limiting for
Aurora A activation and mitotic entry. Our data indicate
a novel regulatory pathway critical for timely mitotic
entry.
Results
Smurf2 and NEDD9 interact
Smurf2 contains WW domains that confer interaction
with PPxY motifs [1,15]. Our previous finding that
Smurf2 localizes to the centrosome and is required for
proper mitotic progression [6] prompted us to examine
whether Smurf2 physically interacts with other proteins
known to regulate mitosis at the centrosome. Database
analyses identified several centrosomal proteins that
contain PPxY motifs, including Centriolin, LATS1,
LATS2 and NEDD9. Since NEDD9 plays diverse roles
not only in focal adhesion and cell motility but also in
mitotic regulation, we further analyzed the potential
interaction between Smurf2 and NEDD9. NEDD9 con-
tains a PPxY motif at residues 108-111, YQVPPSYQNQ,
within an SH2 binding site-rich domain. The protein
levels of both Smurf2 and NEDD9 rise during late G2
and significantly decline exiting mitosis [6,16]. To maxi-
mize the potential of finding a physical interaction,
HeLa cells were synchronized in mitosis by nocodazole
treatment and then lysates were prepared for co-immu-
noprecipitation assays. Indeed, Smurf2 was readily
detected in NEDD9 immunoprecipitates from mitotic
cells, and reciprocally, NEDD9 was found in Smurf2
immunoprecipitates (Figure 1). Co-immunoprecipitation
of these two proteins was less obvious in an asynchro-
nous cell population. Our data do not exclude that this
interaction could require other proteins, but these data
do suggest that Smurf2 and NEDD9 are in complex
with each other, most abundantly so during mitosis.
Depletion of Smurf2 destabilizes NEDD9
To begin to examine the functional significance of the
Smurf2-NEDD9 interaction, we tested whether Smurf2
affected the level of NEDD9. In particular, we addressed
whether the E3 ligase Smurf2 would directly target
NEDD9 for proteasome-mediated degradation. Contrary
to this speculation, it was consistently observed that
NEDD9 protein levels were decreased by siRNA-
mediated Smurf2 depletion in HeLa cervical carcinoma
cells and CN34 mammary carcinoma cells (Figure 2A),
and U2OS osteosarcoma cells (data not shown). The
decline in NEDD9 protein levels induced by Smurf2
depletion was a post-transcriptional effect as RT-PCR
analysis showed little to no effect on NEDD9 mRNA
level (Figure 2B). To exclude the possibility of off-target
effects exerted by Smurf2 siRNA, we engineered a
Figure 1 Smurf2 physically interacts with NEDD9 during
mitosis. Extracts were prepared from HeLa cells that were either
asynchronous (A) or synchronized at mitosis by the thymidine-
nocodazole protocol (S), and 400 μg proteins were
immunoprecipitated (IP) with the indicated antibodies or normal
immunoglobulin (IgG), followed by immunoblotting (IB) for the
indicated proteins. Forty micrograms of whole cell extracts (10%
WCE) were also subjected to IB for comparison.
Figure 2 Depletion of Smurf2 leads to a decline in NEDD9
protein levels. (A) Depletion of Smurf2 by siRNA (siSm2) leads to
decreased NEDD9 protein levels in HeLa and CN34 cells. (B) Smurf2
does not affect NEDD9 transcript level. RNA samples from HeLa cells
transfected with siSmurf2 were analyzed by RT-PCR for the indicated
transcripts. (C) Forced expression of an siRNA-resistant Smurf2
mutant (Sm2siR) rescues NEDD9 levels in HeLa cells transfected with
siSmurf2. D) NEDD9 depletion does not affect Smurf2 levels. For all
samples, protein from HeLa cells was harvested 48 hours after
transfection, 30 μg total protein was loaded onto gel. For siRNA
transfections, cells were reverse transfected with 50 nM siRNA
(siSmurf2#1, siNEDD9 Smartpool). RT-PCR was performed on cells
treated as described above. RNA was extracted as described in
Methods. For siRNA and DNA transfection, cells were forward
transfected with 50 nM siRNA and 1 μg DNA of either no plasmid,
CMV empty vector, FLAG-Smurf2si-resistant mutant.
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Smurf2 mutant (FLAG-Smurf2si-resistant) that is resistant
to siRNA-mediated knockdown by mutating 4 nucleo-
tides within the siSmurf2#1 target region. Co-transfection
of siSmurf2-treated cells with FLAG-Smurf2si-resistant
mutant significantly restored NEDD9 levels (Figure 2C).
These results show that Smurf2 plays an essential role
in maintaining the stability of NEDD9 protein. To reci-
procally establish whether NEDD9 controls Smurf2
levels, HeLa cells were transfected with NEDD9 siRNA.
NEDD9 depletion had no discernable effect on Smurf2
protein levels (Figure 2D). These data suggest that
Smurf2 positively regulates the level of NEDD9 protein
at the post-transcriptional level.
Regulation of NEDD9 by Smurf2 is mediated by the
proteasome
Since NEDD9 is known to undergo proteasomal degrada-
tion [17], we next examined whether Smurf2 depletion
accelerates this process (Figure 3A). As we expected, the
proteasome inhibitors MG132 and lactacystin substan-
tially restored NEDD9 protein levels in cells with Smurf2
depleted (Figure 3A). To determine whether the protea-
somal degradation of NEDD9 was dependent on polyubi-
quitination, NEDD9 was immunoprecipitated from
Smurf2-depleted HeLa cells treated with MG132, and
then analyzed by immunoblotting with anti-ubiquitin
antibody (Figure 3B). Polyubiquitination of NEDD9 was
significantly enhanced in cells treated with Smurf2
siRNA and MG132, compared with that in cells with
non-specific siRNAs and MG132. These results suggest
that depletion of Smurf2 leads to polyubiquitination and
subsequent degradation of NEDD9.
Overexpression of Smurf2 stabilizes NEDD9 in a ligase-
independent manner
We next asked if forced overexpression of Smurf2
increased NEDD9 levels. HeLa cells were co-transfected
with Myc- or GFP-tagged NEDD9 and FLAG- or
mCherry-tagged Smurf2, and then analyzed by immuno-
blotting for each tag (Figure 4). Levels of Myc- or
GFP-tagged NEDD9 were substantially increased by co-
transfection with FLAG- or mCherry-tagged Smurf2,
compared with plasmid controls. The upregulation of
NEDD9 by co-transfection with Smurf2 was not a by-
product of altered cell cycle progression, because flow
cytometric analysis after transfection with GFP-NEDD9
and mCherry-Smurf2 showed that the percentages of
transfected cells in G1, S and G2/M were not signifi-
cantly affected by Smurf2 co-transfection at the time
points examined (data not shown). As Smurf2 is an E3
ligase, we next asked if the Smurf2 enzymatic activity
was required for it to affect NEDD9 expression. Interest-
ingly, co-expression of a catalytically inactive Smurf2
mutant (C716A, targeting the HECT domain) also upre-
gulated the levels of exogenously expressed NEDD9.
These results provide support for the idea that Smurf2
Figure 3 Depletion of Smurf2 results in enhanced
polyubiquitination and proteasomal degradation. (A) Decline in
NEDD9 induced by siSmurf2 (Sm2) was rescued by treatment with
proteasomal inhibitors. siRNA-transfected HeLa cells were treated
with either 2 μM MG132, 5 μM lactacystin (LACT) or equivalent
volume DMSO for 4 h. (B) siSmurf2 leads to polyubiquitination of
NEDD9. NEDD9 was immunoprecipitated from HeLa cells
transfected with siRNA and treated with MG132.
Figure 4 Forced expression of wild-type or catalytically
inactive Smurf2 stabilizes NEDD9 protein. (A) HeLa cells were
co-transfected with Myc-NEDD9 and either empty vector (pcDNA)
or FLAG-Smurf2 (Sm2). Similar conditions were used to co-transfect
with GFP-NEDD9 and either empty vector (mCherry) or mCherry-
Smurf2. After 48 h, cells were harvested for immunoblotting. (B)
HeLa cells were co-transfected with the indicated plasmid as
described in (A). Co-transfection of wild-type (WT) or catalytically
inactive (C716A) Smurf2 increased NEDD9 expression.
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positively regulates NEDD9, and suggest that this action
may be independent of the activity of Smurf2 as an E3
ligase.
Smurf2 depletion results in delayed mitotic entry with
impaired Aurora A activation
We recently demonstrated that Smurf2 regulates the
spindle assembly checkpoint during early to mid-mito-
sis, via action controlling the stability of Mad2 protein
[6]. HeLa cells depleted of Smurf2 exhibit perturbed
chromosome segregation, premature anaphase onset,
and the inability to arrest in prometaphase in response
to nocodazole or taxol. The finding that Smurf2
controls NEDD9 levels prompted us to examine
the impact of Smurf2 depletion on mitotic entry, as
NEDD9 has been demonstrated to be required
for timely entry into mitosis with proper Aurora
A activation [14]. HeLa cells transfected with Smurf2
siRNA, NEDD9 siRNA or control siRNAs were syn-
chronized at early S by double thymidine block [6],
released into synchronous cell cycle progression and
analyzed at prometaphase and metaphase (Figure 5).
Immunofluorescence microscopy showed that Thr288
phosphorylation of Aurora A at centrosomes, reflecting
auto-phosphorylation and activation, was significantly
diminished to almost undetectable levels in mitotic
cells with Smurf2 depletion, relative to control cells at
the same time point. Immunoprecipitation followed by
immunoblotting detection of Thr288 phosphorylation
separately confirmed that Smurf2 depletion reduced
Aurora A activation (Figure 6).
To determine whether these results reflected a specific
requirement of Smurf2 for Aurora A activation or a gen-
eral effect on mitotic signaling, we performed immuno-
blotting for representative mitosis-regulatory proteins at
0-12 hours after release from thymidine-induced S phase
arrest (Figure 7). In control cells, the active form of Aurora
A with Thr288 phosphorylation appeared around 8-9
hours after release, which coincided with or was followed
by downregulation of Cyclin A and a migration shift of
Smurf2 due to mitosis-specific phosphorylation. Further,
CDK1 inhibition as measured by phosphorylation at Tyr15
is relieved beginning 9 hours post-release. Aurora A acti-
vation was substantially diminished in cells transfected
with NEDD9 siRNA, as demonstrated previously [14].
Similar diminishment in Thr288 phosphorylation of Aur-
ora A was observed in cells transfected with Smurf2
siRNA, which also displayed a significant decrease in
NEDD9 levels. Consistently, downregulation of Cyclin A2
and Emi1 and the mitosis-associated shift in Smurf2
migration were delayed in cells with NEDD9 depletion or
Smurf2 depletion. In addition, the master mitotic regulator
CDK1 remained in its inhibited, Tyr15-phosphorylated
form longer in cells depleted of Smurf2. Taken together,
these data suggest that Smurf2 is a determining factor of
NEDD9 levels and Aurora A activation in mitotic cells.
Discussion
In the present study we have demonstrated the novel
regulation of the multi-functional scaffold protein
NEDD9 by the WW-HECT protein Smurf2. Physical
Figure 5 Depletion of Smurf2 inhibits Aurora A activation at
the centrosome. HeLa cells were transfected with control non-
specific dsRNAs (siNS) or siRNA against Smurf2. At 40 h post-
transfection, cells were fixed, stained with DAPI and pan-Aurora A or
Thr288 phosphorylation-specific (pT288) Aurora A antibody, and
subjected to immunofluorescence microscopy. Smurf2-depleted
cells exhibit a marked reduction in Thr288 phosphorylated (active)
Aurora A at the spindle poles.
Figure 6 Depletion of Smurf2 decreases the activated pool of
Aurora A. Lysates of control and Smurf2 depleted HeLa cells were
first immunoprecipitated with pan-Aurora A antibody and then
western blots were probed with antibody specific for Thr288
phosphorylated active Aurora-A.
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interaction with Smurf2 leads to stabilization of NEDD9
protein via suppression of polyubiquitination and subse-
quent proteasomal degradation. Interestingly, stabiliza-
tion does not appear to depend on the E3 ligase activity
of Smurf2. Depletion of Smurf2, as well as NEDD9
depletion, results in impaired activation of Aurora A at
the G2/M boundary. These results support the notion
that Smurf2 is a critical regulator of entry into mitosis,
extending our recent study on the role for Smurf2 in
Mad2 regulation and the Spindle Assembly Checkpoint.
Aurora A activation during late G2 is a critical step for
commitment to mitosis, and prerequisite for proper acti-
vation of Cyclin B-CDK1 and other mitotic kinases [13].
Centrosomal Aurora A activity governs the timing of
mitotic entry, triggering nuclear envelop breakdown at
prophase [18]. Recent studies demonstrated the require-
ment for NEDD9 in Aurora A activation and suggested
that this scaffold protein is a critical component of
mitosis regulation [12,14]. NEDD9 expression is regu-
lated in a cell cycle-dependent manner and peaks in G2
and M, when it accumulates at the centrosome together
with Aurora A. NEDD9 together with other Aurora A
activators such as TPX2 and Ajuba stimulates autopho-
sphorylation of Aurora A at Thr288, which is required
for full activation of the kinase. Aurora A then phos-
phorylates NEDD9 at Ser296, leading to dissociation of
the complex and allowing Aurora A to interact with
other substrates. Our finding that Smurf2 promotes
Aurora A activation does not exclude possible effects of
Smurf2 on other Aurora A regulators such as TPX2 and
Ajuba. The mitotic function of NEDD9 could be related
to its key role in focal adhesion-dependent migration
[reviewed in [19,20]]. NEDD9 associates with focal adhe-
sion kinase (FAK) and a Src family kinase. Subsequent
Src-mediated phosphorylation of NEDD9 creates active
SH2 sites, which bind to the adaptor protein Crk. Crk
association subsequently recruits DOCK180 and C3G,
eliciting signals to the GTPases Rac and Rap, respec-
tively. A number of recent studies suggested the pre-
sence of crosstalk between the focal adhesion
attachment signaling and the centrosome-based mitosis
signaling [21-23]. Multiple components of integrin-
mediated migratory signaling including NEDD9 and Pak
have been shown to associate with and activate Aurora
A at the centrosome. Another centrosomal protein
GIT1, which is required for Pak localization to the cen-
trosome, binds to the focal adhesion protein Paxillin.
Furthermore, the mitotic LATS1 kinase in complex with
the focal adhesion protein Zyxin localizes to microtu-
bules proximal to the centrosome and regulates mitotic
initiation [24]. It is noteworthy that LATS1 also pos-
sesses a PPxY motif for potential association with the
WW domains of Smurf2, although its significance
remains to be determined.
Smurf2 also plays multiple roles in cell migration and
mitotic regulation [5,25]. Among the substrates for
Smurf2-mediated polyubiquitination are TGF-b type 1
receptor, the GTPase Rap1B, and its closely related
homolog, Smurf1 [1,8,26]. Smurf1 polyubiquitinates
RhoA, talin head domain and hPEM2 [27,28]. These pro-
teins are all involved in the control of cell migration.
Moreover, a recent study demonstrated that Smurf2 and
Smurf1 are critical regulators of planar cell polarity. Mice
deficient for Smurf1 and Smurf2 display defects in planar
cell polarity that leads to perturbed stereocilia alignment
in neurosensory cells of the cochlea and failed closure of
the neural tube [7]. Our recent work provided evidence
that Smurf2 is also a regulator of mitosis [6]. Smurf2
expression fluctuates during the cell cycle, with a peak
around the G2/M boundary. Smurf2 localizes to the cen-
trosome from interphase until late mitosis, when it
moves to the mitotic midbody together with the chromo-
some passenger complex. Smurf2-depleted cells exhibit
multiple defects associated with impaired spindle assem-
bly checkpoint such as premature activation of the ana-
phase promoting complex (APC) in prometaphase,
misaligned and lagging chromosomes during the meta-
phase to anaphase transition, and failed cytokinesis.
These defects are attributable partly to a marked decrease
in the spindle checkpoint protein Mad2, as a conse-
quence of accelerated proteasomal degradation. The pre-
sent study demonstrates that Smurf2 depletion also
downregulates NEDD9, which results in impaired Aurora
A activation and delayed mitotic entry. The integrin sig-
naling including NEDD9, which governs the basal cell
adhesion to the extracellular matrix, determines the
Figure 7 Depletion of Smurf2 results in the lack of Aurora A
activation and delayed mitotic entry. HeLa cells were transfected
with siRNA against Smurf2 or control dsRNAs (siNS), synchronized at
early S phase by a double thymidine protocol, and released into
synchronized progression toward mitosis. Cells were harvested at
the indicated times after release for immunoblotting with the
antibodies shown on right.
Moore et al. Cell Division 2010, 5:22
http://www.celldiv.com/content/5/1/22
Page 5 of 8
orientation of the cell division plane together with the
cadherin-mediated planar adhesion signaling. Thus, the
crosstalk involving Smurf2, NEDD9 and Aurora A may
function as effectors of attachment-sensing mitotic
checkpoint. Also, Smurf2 and NEDD9 may collaborate in
RhoA activation critical for not only migration but also
cytokinesis [26,29]. Taken together, these data imply that
in proliferating cell types Smurf2 controls various protein
complexes that are critical for different phases of mitosis,
i.e., the NEDD9-Aurora A centrosomal complex in G2
and prophase, the Mad2 spindle checkpoint complex in
prometaphase, and the RhoA complex in cytokinesis.
Since Smurf2 is known to play diverse roles in the biol-
ogy of non-proliferative differentiated cells, it will be
important to determine whether the mitosis-promoting
function of Smurf2 is one of cell type-specific events or a
more conserved mechanism of proliferation.
The mechanism with which Smurf2 controls NEDD9
stability remains to be elucidated. The stability of
NEDD9 protein is regulated by phosphorylation and
subsequent polyubiquitination [30]. In response to TGF-
b signals, NEDD9 undergoes polyubiquitination facili-
tated by physical interaction with Smad3 [17,31]. Addi-
tionally, another member of the WW-HECT family,
AIP4 (atrophin 1 interacting protein 4)/Itch, can also
target NEDD9 for degradation in a TGF-b-dependent
manner [32]. Further, APC/CCdh1 targets NEDD9 for
degradation at the end of mitosis [31]. We found that
phosphorylated and hyperphosphorylated NEDD9 are
stabilized by Smurf2. Though Smurf2 is known as a
negative regulator of TGF-b signaling, the NEDD9-stabi-
lizing action of Smurf2 seems unlikely to depend on
altered TGF-b signaling. HeLa cells are not typically
responsive to TGF-b signals [33]. Further, we found that
depletion of Smad3, Smurf1, or AIP4/Itch failed to res-
cue NEDD9 levels in cells with Smurf2 depletion (data
not shown). We believe that the Smurf2 regulation of
NEDD9 in mitotic entry occurs through a different
mechanism from Smurf2 regulation of Mad2 in the
Spindle Assembly Checkpoint. It is likely that Smurf2
interacts with Mad2 and NEDD9 at distinct subcellular
locations during mitosis. At the kinetochore and its
proximity, Smurf2 may target an intermediary E3 ligase
for degradation to stabilize Mad2. In contrast, Smurf2 at
the centrosome binds and stabilizes NEDD9 apparently
in a ligase-independent fashion. Currently several
hypotheses are being evaluated regarding NEDD9 stabi-
lization by Smurf2. Our observation that the catalytically
inactive mutant of Smurf2 could also stabilize NEDD9
levels excludes the possibility that Smurf2 targets an
intermediary ligase for NEDD9 degradation. Consistent
with the ligase-independent function of Smurf2 is a pre-
vious report that overexpression of wild-type or ligase-
dead Smurf2 induces senescence [34]. Further, AIP4/
Itch stabilizes Smad7/TGFbRI complex independently of
its ligase activity [35]. Smurf2 also interacts with Smad7,
and does not immediately induce its degradation [1].
Interestingly, NEDD9 has been shown to interact with
Smad7 [36]. These data also exclude a model in which
NEDD9 is stabilized by monoubiquitination. Smurf2
may sequester NEDD9 away from locations in the cell
where it could encounter its E3 ligase. Alternatively,
Smurf2 may instead mask regulatory epitopes for ubi-
quitination. Smurf2 may serve as an adaptor for an uni-
dentified regulator that counteracts with another E3
ligase promoting NEDD9 degradation. The ongoing stu-
dies are expected to identify the E3 ligase that targets
NEDD9 for degradation in response to Smurf2 deple-
tion, and to reveal missing components of the Smurf2-
dependent mitosis-regulatory pathway.
Both Smurf2 and NEDD9 are overexpressed in multiple
types of cancers. Smurf2 upregulation has been asso-
ciated with poor prognosis in cancers including esopha-
geal squamous cell carcinoma and renal cell carcinoma
[37,38]. Smurf2 has also been found to be upregulated in
breast cancer tissue and cell lines as well as ovarian and
prostate cancer cell lines [39]. Jin and colleagues found
that depletion of Smurf2 by siRNA inhibited migration
and invasion, overexpression of Smurf2 led to enhanced
migration and invasion [39]. Together, these data suggest
that Smurf2 promotes tumor cell migration and invasion.
Increased levels of NEDD9 have been found in lung ade-
nocarcinoma [40], glioblastoma [41], and melanoma [42].
NEDD9 was identified as one of a few critical genes that
mediate metastasis in melanoma [42] and breast cancer
[43]. Mice null for Nedd9 are resistant to MMTV-poly-
oma T-induced tumorigenesis [40], recapitulating the sig-
nificant role for NEDD9 in tumor development. It will be
important to determine whether Smurf2 and NEDD9
levels correlate with each other in human cancers. Future
studies using human cancer specimens should provide
insight into the putative oncogenic interaction of these
two proteins in the regulation of cell cycle progression
and genomic instability of cancer cells.
Conclusion
The present work demonstrates that Smurf2 positively
regulates NEDD9, which is required for Aurora A acti-
vation and proper mitotic entry. These data suggest that
Smurf2 plays diverse roles in mitotic regulation.
Methods
Cell lines and reagents
HeLa human cervical carcinoma cells (ATCC) were cul-
tures under standard conditions of complete medium
containing DMEM, 10% fetal bovine serum (FBS),
2 mM glutamine, 100 units/ml Penicillin/Streptomycin.
CN34 breast cancer cells were cultured as described
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in [44]. Antibodies used in this study are NEDD9/HEF1/
Cas-L (2G9), Ubiquitin (P4D1), normal rabbit IgG, nor-
mal mouse IgG from Santa Cruz Biotechnology (Santa
Cruz, California); Smurf2 from Upstate/Millipore (Lake
Placid, NY); FLAG M2 and b-Actin (Clone AC-15) from
Sigma Aldrich; and Myc from Invitrogen.
Plasmids and siRNA reagents
siRNA was ordered from Dharmacon/Thermo Fisher
Scientific for Smurf2 (#1), NEDD9 (smartpool) and con-
trol (#3). The sequence for siSm2 was 5’-GAUGAGAA-
CACUCCAAUUAUU-3’. NEDD9 and its mutants were
sub-cloned into Myc vector from Sigma Aldrich. FLAG-
Smurf2WT and FLAG-Smurf2(C716A) in pCs2+ vector
were kindly provided by Gerald Thomsen at Stony
Brook University. Smurf2 was sub-cloned into mCherry
vector from Clontech. Smurf2si-resistant was created by
site-directed mutagenesis (Quickchange from Strata-
gene) of FLAG-Smurf2 at 4 nucleotides within the
region targeted by siSmurf2#1: T631C, G634A, T640G,
A643G. For protein and RNA extractions, cells were
reverse transfected with 50 nM siRNA using RNAiMax
from Invitrogen, then harvested 48 h later. When DNA
was transfected, 1 μg of each plasmid per 6D dish was
transfected with Lipofectamine2000 from Invitrogen.
Co-immunoprecipitation
For immunoblotting or immunoprecipitation, cells were
lysted by sonication in lysis buffer as described pre-
viously [6]. Unless otherwise noted, 30 μg total protein
lysate was loaded onto gel. Co-immunoprecipitation was
performed in HeLa cells that were either asynchronous
synchronized at mitosis by 2 mM thymidine 18 h,
release for 9 h, 400 ng/μl nocodazole for 14 h. 400 μg
total protein was incubated with 1.5 μg of antibody
overnight at 4°C. Protein A (for rabbit Smurf2 IPs) or G
(for mouse NEDD9 IPs, both from Zymogen) beads
were added for 1 h 4°C. Immunoprecipitated materials
were loaded onto 2 different gels and probed by Wes-
tern blot accordingly. For immunoprecipitation with
NEDD9 antibody, lysates were pre-cleared with protein
G beads for 30 minutes 4°C before incubation with
NEDD9 antibody. For NEDD9 immunoprecipitation for
ubiquitination, cells were treated for 4 h with 2 μM
MG132 44 h post-transfection. Entire immunoprecipi-
tates were loaded onto one gel, gel was transferred onto
PVDF membrane as usual, then prepared for Ubiquitin
blotting by treatment with 6 M guanidium chloride,
20 mM Tris pH 7.5, 1 mM PMSF (fresh), 5 mM b-mer-
captoethanol (fresh) for 30 minutes, 4°C.
Semi-quantitative RT-PCR
RNA was extracted with Agilent kit, 2 μg RNA was used
to synthesize cDNA with the Invitrogen Superscript II
kit, PCR was performed with 2 μl of cDNA, 27 cycles,
Tm or 50°C.
Immunofluorescence
HeLa cells were grown on coverslips and fixed in ice
cold methanol for 20 minutes to overnight. Centrosome
staining was followed as described previously [6].
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